THE WOODLANDS, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2017.
Financial Results
Net loss for the three month period ended March 31, 2017 was ($5.9) million, or ($0.22) per share, as compared to net loss of ($4.8) million, or ($0.20) per share, for the same period in 2016. The increase in net loss for the three month period ended March 31, 2017 as compared to the same period in 2016 was primarily due to expenses associated with the departure of the Company’s former President and Chief Executive Officer, partially offset by decreased clinical development expenses related to the Company’s Proellex® and enclomiphene product candidates.
